PT1385522E - Associação contendo um inibidor de transdução de sinais e um derivado da epotilona - Google Patents

Associação contendo um inibidor de transdução de sinais e um derivado da epotilona Download PDF

Info

Publication number
PT1385522E
PT1385522E PT02744903T PT02744903T PT1385522E PT 1385522 E PT1385522 E PT 1385522E PT 02744903 T PT02744903 T PT 02744903T PT 02744903 T PT02744903 T PT 02744903T PT 1385522 E PT1385522 E PT 1385522E
Authority
PT
Portugal
Prior art keywords
combination
signal transduction
transduction inhibitor
epothilone derivative
derivative
Prior art date
Application number
PT02744903T
Other languages
English (en)
Inventor
Peter Traxler
Markus Wartmann
Elisabeth Buchdunger
John David Rothermel
Terence O'reilly
Ralf Brandt
Carl-Henrik Heldin
Arne Oestman
Kristian Pietras
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0104840.4A external-priority patent/GB0104840D0/en
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Publication of PT1385522E publication Critical patent/PT1385522E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT02744903T 2001-02-27 2002-02-26 Associação contendo um inibidor de transdução de sinais e um derivado da epotilona PT1385522E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104840.4A GB0104840D0 (en) 2001-02-27 2001-02-27 Use of organic compounds
US33904001P 2001-10-30 2001-10-30

Publications (1)

Publication Number Publication Date
PT1385522E true PT1385522E (pt) 2009-09-04

Family

ID=26245767

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02744903T PT1385522E (pt) 2001-02-27 2002-02-26 Associação contendo um inibidor de transdução de sinais e um derivado da epotilona

Country Status (23)

Country Link
US (1) US7723339B2 (pt)
EP (1) EP1385522B1 (pt)
JP (1) JP4499359B2 (pt)
KR (1) KR100848197B1 (pt)
CN (1) CN1511036B (pt)
AT (1) ATE434438T1 (pt)
AU (1) AU2002308218B2 (pt)
BR (1) BR0207649A (pt)
CA (1) CA2439268C (pt)
CY (1) CY1109347T1 (pt)
DE (1) DE60232719D1 (pt)
DK (1) DK1385522T3 (pt)
ES (1) ES2326264T3 (pt)
HK (1) HK1062266A1 (pt)
IL (2) IL157466A0 (pt)
MX (1) MXPA03007729A (pt)
NO (1) NO325416B1 (pt)
NZ (1) NZ527764A (pt)
PL (1) PL207197B1 (pt)
PT (1) PT1385522E (pt)
RU (1) RU2313345C2 (pt)
SK (1) SK287489B6 (pt)
WO (1) WO2002067941A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69734362T2 (de) * 1996-12-03 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, zwischenprodukte dazu, analoga und verwendungen davon
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
BR0209647A (pt) * 2001-05-16 2004-07-27 Novartis Ag Combinação que compreende n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e um agente quimioterapêutico
EP1704863A3 (en) * 2001-05-16 2010-11-24 Novartis AG Combination comprising N-5-4-(4-Methyl-Piperazino-Methyl-)Benzoyla Mido]-2-Methylphenyl -4-(3-Pyridyl)-2Phyrimidine-amine and a chemotherapeutic agent
JP2005507424A (ja) * 2001-10-29 2005-03-17 ノバルティス アクチエンゲゼルシャフト 固形腫瘍の処置における７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体の使用
DE60330407D1 (de) 2002-08-23 2010-01-14 Sloan Kettering Inst Cancer Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
EP2029156A4 (en) * 2006-05-01 2010-07-21 Univ Southern California POLY THERAPY FOR TREATING CANCER
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US20110300150A1 (en) 2010-05-18 2011-12-08 Scott Eliasof Compositions and methods for treatment of autoimmune and other disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
TW225528B (pt) 1992-04-03 1994-06-21 Ciba Geigy Ag
BR9609617B1 (pt) * 1995-07-06 2010-07-27 derivados de 7h-pirrol[2,3-d]pirimidina, e composição farmacêutica.
JP4274583B2 (ja) 1996-11-18 2009-06-10 ゲゼルシャフト・フュア・ビオテクノロギッシェ・フォルシュンク・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃ，ｄ，ｅ及びｆ、製造と薬剤
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
AU5036999A (en) * 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
CN1340053A (zh) * 1999-02-11 2002-03-13 舍林股份公司 依泊昔酮衍生物、其制备方法及药物用途
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung

Also Published As

Publication number Publication date
CA2439268C (en) 2010-01-19
CA2439268A1 (en) 2002-09-06
CN1511036B (zh) 2010-05-05
US7723339B2 (en) 2010-05-25
MXPA03007729A (es) 2003-12-04
BR0207649A (pt) 2004-03-09
KR20040025900A (ko) 2004-03-26
AU2002308218B2 (en) 2005-11-10
SK287489B6 (sk) 2010-11-08
NZ527764A (en) 2006-01-27
WO2002067941A3 (en) 2003-11-20
SK10712003A3 (sk) 2004-02-03
WO2002067941A2 (en) 2002-09-06
JP4499359B2 (ja) 2010-07-07
DK1385522T3 (da) 2009-10-12
KR100848197B1 (ko) 2008-07-24
DE60232719D1 (de) 2009-08-06
NO325416B1 (no) 2008-04-21
IL157466A (en) 2012-04-30
ATE434438T1 (de) 2009-07-15
CN1511036A (zh) 2004-07-07
PL363288A1 (en) 2004-11-15
EP1385522B1 (en) 2009-06-24
US20040132754A1 (en) 2004-07-08
PL207197B1 (pl) 2010-11-30
RU2313345C2 (ru) 2007-12-27
IL157466A0 (en) 2004-03-28
WO2002067941A8 (en) 2003-12-18
NO20033769L (no) 2003-08-25
CY1109347T1 (el) 2014-07-02
NO20033769D0 (no) 2003-08-25
ES2326264T3 (es) 2009-10-06
EP1385522A2 (en) 2004-02-04
JP2004527493A (ja) 2004-09-09
HK1062266A1 (en) 2004-10-29
RU2003127392A (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
CY1109347T1 (el) Συνδυασμος που αποτελειται απο εναν αναστολεα μεταλλαγης σηματος και ενα παραγωγο εποθιλονης
PL371466A1 (en) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents
IL176070A0 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND THE USE THEREOF
NO20076323L (no) Kombinasjon omfattende N-{5-[4-(4-metylpiperazinometyl)-benzoylamido]-2-metyl-fenyl}-4-(3-pyridyl)-2-pyrimidinamin og en aromataseinhibitor, anvendelse av kombinasjonen samt farmasøytisk preparat
AU2003259521A8 (en) Combination of a) n-{5-(4-(4-methyl-piperazino-methyl)-benzoylamido)-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
NO20023319D0 (no) Substituerte glutarimider og deres anvendelse som inhibitorer av IL-12-produksjonen
EE200300041A (et) Tsükliin-sõltuvate kinaaside N-[5-[[[5-alküül-2-oksasolüül]metüül]tio]-2-tiasolüül]karboksamiidinhibiitorid
NO20043902L (no) Kontrollert syntese av ziprasidon og sammensetninger derav
ATE339197T1 (de) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3- 4-pyrimindin-3-yl)pyrimidin-2-yl-amino)phenyl)- benzamide zur behandlung von ang-ii vermittelt krankheiten
WO2002028829A3 (en) Peptide deformylase inhibitors
ATE289306T1 (de) N-(5-(((5-alkyl-2-oxazolyl)methyl)thio)-2- thiazolyl carboxamide als inhibitoren cyclinabhängiger kinasen
DE60332862D1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
SG127737A1 (en) Piperidine and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
NO20023785D0 (no) Vanndispergerbar formulering av paroxetin
NO20034124L (no) Sammensetning av et taxan og en cyclinavhengig kinaseinhibitor
ATE476183T1 (de) Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
ATE348615T1 (de) 2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
EE200000638A (et) 1-(6-kloronaft-2-üülsulfonüül)-4-[4-(4-püridüül)bensoüül]-piperasiini vähendatud osakesesuurusega vorm
DE60204791D1 (de) Synthese von 4-(piperidyl) (2-pyridyl)methanon-(e)-o-methyloxim und seinen salzen
FR2842018B3 (fr) Micro-composant incluant un element inductif du type inductance ou transformateur
SI1436282T1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(e)-o-methyloxime and its salts
HU0401645D0 (en) Alpha crystal form of 4-(4-methyl-piperazine-1-yl-methyl)-n-[4-methyl-3-(4-pyridine-3-yl)-pyrimidine-2-yl-amino]-phenyl)-benzamide monomethanesulfonate